William Doyle - Zoetis Director

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:3em;padding-top: 38px;;'>ZTS</div>
ZTS -- USA Stock  

Report: 6th of August 2020  

  Director
Mr. William F. Doyle is Independent Director of Company. Mr. Doyle is Member of Pershing Square Capital Management L.P., a registered investment advisor, since 2013, where he serves as a senior advisor focused on the healthcare industry. Since 2003, Mr. Doyle was the Managing Partner of WFD Ventures LLC, an investor in earlystage human healthcare device, drug and service companies. Previously, as an executive at Johnson Johnson, Mr. Doyle was a member of Johnson Johnsons Consumer Pharmaceuticals and Medical Devices Group Operating Committee with responsibility for licensing, acquisitions and strategy. He was also Chairman of Johnson Johnsons Medical Devices Research and Development Council, Worldwide President of BiosenseWebster, and a member of the internal boards of directors of Cordis Corporationrationration and Johnson Johnson Development Corporationrationration . Earlier, Mr. Doyle was a management consultant with McKinsey Co. working in McKinseys Global Healthcare practice group. Mr. Doyle serves as chairman of the board of Novocure Ltd., a public company since October 2, 2015, that is commercializing a new therapeutic modality for glioblastoma and other solid tumors and is a member of the boards of several private companies, including Optinose, Inc., a developer of new therapies for migraine, nasal inflammatory disease and autism. In addition, Mr. Doyle is a member of the Deans Board of Advisors of Harvard Business School Harvard Business Schools Healthcare Advisory Board and the MIT Corporationrationrations visiting committee for undergraduate education
Age: 52  Director Since 2015  MBA    
973 822-7000  www.zoetis.com
Doyle holds a bachelor?s degree in materials science and engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

William Doyle Latest Insider Activity

Zoetis Management Efficiency

Zoetis Inc has Return on Asset of 12.48 % which means that on every $100 spent on asset it made $12.48 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 63.55 %, implying that it generated $63.55 on every 100 dollars invested. Zoetis management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. As of 07/13/2020, Return on Sales is likely to grow to 0.28, while Return on Investment is likely to drop 19.96. Zoetis Tax Assets are relatively stable at the moment as compared to the past year. Zoetis reported last year Tax Assets of 110.4 Million. As of 07/13/2020, Revenue to Assets is likely to grow to 0.66, while Current Assets are likely to drop slightly above 4 B. Zoetis Total Liabilities is relatively stable at the moment as compared to the past year. Zoetis reported last year Total Liabilities of 8.84 Billion. As of 07/13/2020, Tax Liabilities is likely to grow to about 470.9 M, while Current Liabilities is likely to drop slightly above 1.5 B.
The company has 6.69 B in debt with debt to equity (D/E) ratio of 2.43, meaning that the company heavily relies on borrowing funds for operations. Zoetis Inc has a current ratio of 2.71, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Patrick OSullivanAllergan Plc
2013
Stephen SangerPfizer Inc
2009
Gary CohenPerrigo Company Plc
2009
Adriane BrownAllergan Plc
2017
Leo PuriDr Reddys Laboratories
2018
William YoungVertex Pharmaceuticals Incorpor
2014
Ellen HoffingPerrigo Company Plc
2008
Michael BrownRegeneron Pharmaceuticals
1991
Wyllie CornwellPfizer Inc
1997
Michael GallagherAllergan Plc
2015
Jeffrey KindlerPerrigo Company Plc
2017
Ron TaylorAllergan Plc
2013
Don CornwellPfizer Inc
1997
Peter McDonnellAllergan Plc
2015
Ronald TaylorAllergan Plc
2013
Arthur RyanRegeneron Pharmaceuticals
2003
Margaret McGlynnVertex Pharmaceuticals Incorpor
2011
Geoffrey ParkerPerrigo Company Plc
2016
Shlomo YanaiPerrigo Company Plc
N/A
Omkar GoswamiDr Reddys Laboratories
2000
Marc TessierLavigneRegeneron Pharmaceuticals
2011

Company Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on BATS Exchange. It employs 10600 people.Zoetis Inc (ZTS) is traded on BATS Exchange in USA and employs 10,600 people.

Zoetis Inc Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director
William Steere, Independent Director
Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module

Also Currentnly Active

<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:1.7em;padding-top:4px;;'>S</div>
Sold over 300 shares of
six days ago
Traded for 8.62
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>GM</div>
Sold over 100 shares of
six days ago
Traded for 25.24
<div class='circular--portrait-small' style='font-weight: 700;background:#800000;color: #F8F8FF;font-size:0.9em;padding-top: 12px;;'>XOM</div>
Sold over 60 shares of
six days ago
Traded for 44.08
Check out Your Current Watchlist. Please also try Aroon Oscillator module to analyze current equity momentum using aroon oscillator and other momentum ratios.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page